Microbot Medical® Secures its First Office-Based Lab (OBL) Customer for the LIBERTY® Endovascular Robotic SystemGlobeNewsWire • Tuesday
Microbot Medical® Attending Key Medical Conference to Engage with Decision-makers as it Continues to Expand Presence Across the U.S.GlobeNewsWire • 10/23/26
Microbot Medical® Granted Multiple New Patents, Further Strengthening Its Global Intellectual Property PortfolioGlobeNewsWire • 10/20/26
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in IsraelGlobeNewsWire • 10/06/26
Microbot Medical Inc. (MBOT) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/11/26
Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second QuarterGlobeNewsWire • 08/11/26
Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual MeetingGlobeNewsWire • 07/21/26
Microbot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026GlobeNewsWire • 07/07/26
Microbot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing LeaderGlobeNewsWire • 06/30/26
Microbot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic SystemGlobeNewsWire • 06/25/26
Microbot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic SystemGlobeNewsWire • 06/23/26
Microbot Medical® Enters Into an Agreement to Expand Access for America's Veteran and Military Patient PopulationsGlobeNewsWire • 06/16/26
Microbot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic SystemGlobeNewsWire • 06/09/26
Microbot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic SystemGlobeNewsWire • 06/02/26
Microbot Medical® Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY® Endovascular Robotic SystemGlobeNewsWire • 05/26/26
After Plunging 22.6% in 4 Weeks, Here's Why the Trend Might Reverse for Microbot Medical (MBOT)Zacks Investment Research • 05/19/26
Microbot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary BercuGlobeNewsWire • 05/15/26
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026GlobeNewsWire • 05/14/26
Microbot Medical Inc. (MBOT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/13/26
Microbot Medical®'s LIBERTY® Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial SitesGlobeNewsWire • 05/05/26
Microbot Medical® Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)GlobeNewsWire • 04/30/26